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Objective: Patients with diabetes often present with pedal wounds resistant to standard
wound healing modalities and become chronic in nature. These chronic wounds in dia-
beticpatientshaveahighincidenceofcomplicationsincludinginfectionandamputation.
Negative pressure wound therapy has been found to facilitate healing of the stagnant
pedal wound. This protocol was designed to determine wound closure rates using a
unique negative pressure wound therapy system that delivers vacuum-assisted wound
closure with a simultaneous irrigation feature (Svedman Wound Treatment System).
Methods: A prospective single center study was conducted in adults with diabetic foot
ulcers ≥cm2 or more in size showing no signs of clinical infection, and having adequate
blood ﬂow. Patients received dressing changes and irrigation on a standard regimen
with weekly wound assessments for a minimum of 6 weeks. Results: 11 women and 8
men with a mean wound size of 2.4 cm × 2.2 cm were treated with the device. A total
of 14 of /19 (74%) patients healed completely, with a median healing time of 34 days
(range, 9-114). Eleven of 19 patients (58%) healed within the 6-week evaluation period.
For the 5 patients who did not heal completely with the device, other treatments were
utilized, including further wound debridement, muscle ﬂaps, and skin grafting proce-
dures. Conclusions: Negative pressure wound therapy with integrated irrigation was
well tolerated by the patients without complications related to the device application or
irrigation feature. The data clearly suggests that this technology may be a promising
alternative for the chronic nonhealing diabetic wound.
The rising prevalence of diabetes is a well-established fact; the number of diagnosed
patients is tripling in the United States from 1980 to 2007.1 As of 2007, 23.6 million people
in the United States had diabetes, which is 7.8% of the total population.2 The consequences
of foot ulcers associated with diabetic neuropathy include morbidity and mortality as well
as signiﬁcant increases in the health care costs of this patient population. Of those 40 years
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and older with diabetes, 30% experience reduced sensation in their feet,2 and the annual
cost of diabetic neuropathy is estimated to be $10.91 billion in the United States alone.3
In patients with diabetes, the age-adjusted prevalence of a history of foot ulcers is 12.7%
(95% CI: 11.9-13.6),4 some of these wounds resulting in complications such as the need
for lower extremity amputations. In the United States, approximately 71 000 nontraumatic
amputations of the lower limb occurred in patients with diabetes in 2004.2
Previous studies in patients with diabetes have demonstrated that negative pressure
wound therapy (NPWT) facilitates healing in difﬁcult wounds and reduces healing times5-7
resultinginlowerhealthcarecosts.7,8 Thepurposeofthistrialwastodeterminetheefﬁcacy
of NPWT with irrigation in the diabetic wound utilizing the Svedman Wound Treatment
System (Svedman Wound Treatment System, Innovative Therapies, Inc., Gaithersburg,
Maryland). This serves as the ﬁrst prospective clinical study using the Svedman device.
The prospective single center single arm trial was instituted using the Svedman Wound
TreatmentSystemwithirrigation9 inaseriesof20diabeticpatientswithchronicnonhealing
foot ulcers. Wound closure rates and outcomes were assessed, in addition to the safety of
the device.
METHODS
This was a 6-week, single arm, prospective trial. The study protocol was approved by the
Western Institutional Review Board and informed consent was obtained from all patients
prior to enrollment. The primary objective of the study was to determine the wound clo-
sure rates using the Svedman Wound Treatment System with irrigation over the 6-week
evaluation period. Secondary objectives included assessment of the proportion of healing
at 6 weeks and the safety of the device. Foam dressings were changed 3 times weekly with
irrigation at the time of dressing change. A total of 20 patients were consented for the
trial with 19 qualifying for active treatment. The patient that was unable to participate in
active treatment was found to have an ulceration less than 1 cm2 after debridement and
therefore excluded. To obtain a representative sample, diabetic wound patients presenting
to the investigator who had wounds that failed to respond to conservative treatment for
at least 4 weeks were offered the opportunity to join the study if they met inclusion and
exclusion criteria. Eligible patients were men and women older than >18 years diagnosed
with type 1 or type 2 diabetes mellitus and neuropathy with ulceration. The patients’ foot
ulcer was to be ≥ cm2 or more in size at any locationon the foot with no clinicalsigns of in-
fection that had failed a minimum of 4 weeks of conservative care. Wounds were measured
postdebridement to determine the wound size inclusion criterion. Any patients with ulcers
probing to bone (UT Grade IIIA-B)10 were excluded. Patients were also excluded if they
were undergoing dialysis treatment for kidney failure, had a history of poor compliance
with medical treatments, were participating in another clinical trial, were receiving radia-
tion therapy or chemotherapy, had a known or suspected malignancy near the index ulcer,
had an ankle-brachial index less than 0.7, or were without a pulse detectable by Doppler.
At the initial visit (day 0), wounds were debrided and a baseline measurement was
obtained, including the percentage of necrotic tissue (linear scale, 0%-100%). The wound
was measured with a plastic metric ruler and a digital photograph of the wound was
taken at a distance of 30 cm. Each wound also underwent a 3-dimensional imaging and
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acetate tracing study. The NPWT system was then applied in a manner consistent with
the manufacturer’s instructions (Svedman Wound Treatment System, Innovative Therapies,
Inc., Gaithersburg, Maryland).11 Brieﬂy, the wounds were debrided as medically necessary
and a piece of ITI Svedman porous wound foam was cut to the size of the pedal wound. The
inﬂow tubing/lavage catheter and the outﬂow tubing/suction catheter were then covered
with an adhesive dressing, Usage of additional foam for placement of the tubing/catheters
maybeneeded.Suctioncupapplicatorshavesincebeenaddedtothedressingsystembutfor
the purpose of this trial the institutional review board recognized and approved the original
dressing with the tubing/catheter directly inserted into the foam. The suction tubing was
clamped and used for lavage of saline before dressing changes. Continuous pressure was
applied using the default setting of 120 mm Hg. Each patient was provided with a device
user’s manual and was instructed on to how to operate the apparatus and care for their
wound. Patients were ofﬂoaded using a removable cast walker (cbiTCC, Ossur Medical,
Inc, Camarillo, California).
To maintain the very best reproducibility, all dressing changes were performed at the
researchsitebytheinvestigator,subinvestigator,orresearchnurse.Dressingswerechanged
everysecondorthirddaywiththemajorityofallpatientsreturningfordressingchangesev-
ery Monday, Wednesday, and Friday. The progress of wound healing was measured weekly
with acetate 3-dimentional tracings. Before removing dressings, wounds were irrigated
simultaneously with 1000 cc sterile normal saline via the Svedman Wound Treatment Sys-
tem and the irrigation tubing (Irrigation Tubing with SpeedConnect, Innovative Therapies,
Inc.). Upon removal of the dressing, sharp debridement was performed as needed and the
wounds were measured and photographed as previously described. These measurements
were collected until the end of the study, wound healing, or patient withdrawal. All dressing
changes performed in between the regular weekly visits were recorded by study personnel
and documented in the source documentation. Patients had the option of continuing NPWT
if they had not completely healed by the end of 6-week evaluation period. All patients who
were beneﬁting from treatment chose to continue therapy. A clinical photograph of the
Svedman Wound Treatment dressing and device is presented in Figure 1.
RESULTS
A total of 20 patients were enrolled at a single diabetic foot clinic in the United States.
Enrollment was concluded after 20 patients. Treatment was not initiated for 1 white 57-
year-old male patient because of a small wound size at the baseline visit. He was consented
for participation in the study, but after debridement, the wound margins were more epithe-
lialized than initially expected, and the resultant wound size did not meet inclusion criteria.
The patient was therefore excluded and never received active treatment.
Patient characteristics, study disposition, and wound healing over time are presented
in Table 1. A total of 11 women and 8 men were enrolled, 89% white (n = 17) and 11%
African American (n = 2). The median patient age was 64 years, ranging from 43 to 81.
Approximately, half of the wounds occurred on the right lower limb and half on the left
lower limb. The most frequently reported wound locations were right plantar in 4 of /19
(21%) cases, followed by the right heel and left heel with 3 of /19 (16%) cases each. Wound
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sizes at the initial visit ranged from 1.0 cm × 1 . 0c mt o5 . 0c m× 7.0 cm, with a mean
wound size of 2.4 cm × 2.2 cm. The median baseline necrosis was 50% (range, 15-100).
Atotalof14of/19(74%)patientshealedcompletelyusingNPWT,withamediantime
to healing of 34 days (range, 9-124). Eleven of 19 patients (58%) healed within the 6-week
evaluation period. Of those patients healing within 6 weeks, the median baseline wound
size was 2.52 cm2 (range, 1.0-13.72 cm2) and the median baseline amount of necrosis was
40% (range, 15%-80%). Photographs of a representative patient with a plantar forefoot
wound that healed within 3 weeks are presented in Figures 2a to 2c.
Figure 1. The Svedman Wound Treatment System foam dressing and catheters on a plantar ﬁrst
metatarsal pedal wound.
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Three of the 5 remaining patients required additional interventions. Patient 5 required
a skin graft on day 88 to complete healing and was healed on day 113. Patient 6 underwent
a muscle ﬂap and skin graft on day 61, completely healing on day 124. Patient 17 had the
largest wound (5.0 cm × 7.0 cm) in the study with 100% necrosis at baseline. This patient
underwent 2 split-thickness wound grafts after initial NPWT therapy with 60% successful
graft take to the wound but still had not healed as of day 135 and was referred to an outside
specialist for treatment.
One serious adverse event was reported with patient 12 who experienced cellulites
and infection after 12 days in the study. She was admitted to the hospital and although
she was given ample options for limb salvage, having a long history of diabetic ulcers and
infections with her foot, the patient opted for limb amputation. The serious adverse event
was unrelated to the negative pressure therapy device.
Figure 2. A representative patient with a plantar forefoot wound that healed
within 3 weeks. (a) Wound at study entry; (b) After 1 week of negative pressure
therapy with irrigation; (c) Complete healing after second week of therapy.
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The study procedures and NPWT device were well tolerated by the study patients.
Both the NPWT system and the irrigation feature functioned well in all patients enrolled
without any known adverse events related to the unit.
DISCUSSION
In this prospective study conducted in a clinic setting, NPWT using the Svedman Wound
Treatment System with irrigation was successful in facilitating wound closure and healing
in both large and small wounds resulting from complications of diabetic neuropathy and
pressureonthedistallowerlimb.Inthesmallerwounds,NPWTledtorapidepithelialization
with 1 patient experiencing complete healing as quickly as 9 days. In more complicated
cases with larger wounds, complete healing occurred with NPWT, and in some cases,
NPWT with the Svedman system provided a catalyst to create a beneﬁcial granular bed
for tissue grafting in an area that had very little viable tissue at the beginning of therapy.
Therefore, the Svedman Wound Treatment System may not only be a viable option for
both granulation and epithelialization of a diabetic wound but may also serve as a catalyst
to grow granular tissue and facilitate other procedures that may lead to complete wound
healing.
Preventing diabetic ulcers from progressing in depth and becoming infected and
developing into more serious conditions is not only clinically beneﬁcial but has a positive
impact on health care resources. In a retrospective study of claims data from patients
with diabetes, Stockl et al12 reported that patients who experienced complications such
as wounds probing to bone or those requiring amputation had greater costs related to
their ulcers when compared with patients who did not progress (US$20 136 vs US$3063,
respectively; P < .0001). In a recent prospective study conducted in Europe, patients whose
foot ulcers healed had an associated cost of €7722 vs €20064 for patients who did not
heal within a 12-month time frame.13 Given the high costs of nonhealing wounds and the
associated negative impact on patient quality of life, outpatient interventions that prevent
ulcer progression and promote healing are of beneﬁt to patients and clinicians.
This study enrolled a small sample with a large number of the wounds being smaller
than the mean wound size and did not have a comparator group; yet, several useful conclu-
sions may be derived. The procedures and device were well tolerated by the study patients,
who made up a diverse and representative convenience sample treated in a real-world
setting. In addition, patients who healed during the study had diverse wound sizes and
locations, suggesting that the device may be utilized in a variety of locations in the diabetic
foot. Overall, the study results suggest that the Svedman Wound Treatment System was
effective in wounds of all sizes, both large and small, in not only providing outstanding
granulation but also signiﬁcant epithelialization with the majority of wounds healing com-
pletely without any other modality applied. Further studies involving the irrigation feature
should be considered, with daily irrigation possibly providing additional beneﬁt not only
to the diabetic wound but also posttraumatic wounds and decubitus ulceration. In addition,
a study with a larger mean wound size may be considered, although most pedal wounds
are by nature small but difﬁcult to heal with standard therapy. Patient compliance also
plays a large role in wound healing. Although the patients were each given an ofﬂoading
boot with strict instructions to remain in the boot with any ambulation, future studies may
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consider an activity-monitoring device to better assess patient compliance. Lastly, a com-
parator trial to other forms of negative pressure wound management may be considered to
determine whether the Svedman Wound Treatment System with its irrigation feature could
demonstrate superiority.
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